CY1124288T1 - Cmv εμβολια - Google Patents

Cmv εμβολια

Info

Publication number
CY1124288T1
CY1124288T1 CY20211100578T CY211100578T CY1124288T1 CY 1124288 T1 CY1124288 T1 CY 1124288T1 CY 20211100578 T CY20211100578 T CY 20211100578T CY 211100578 T CY211100578 T CY 211100578T CY 1124288 T1 CY1124288 T1 CY 1124288T1
Authority
CY
Cyprus
Prior art keywords
reactivation
cytomegalovirus infections
cmv vaccine
vaccines
methods
Prior art date
Application number
CY20211100578T
Other languages
English (en)
Inventor
Klaus Orlinger
Karen Lingnau
Thomas Monath
Farshad Guirakhoo
Gerhard Fuhrmann
Katherine Cohen
Vera BAUMGARTL-STRASSER
Andreas ASPÖCK
Manuela KAINER
Bernhard BRIM
Bettina KIEFMANN
Elizabeth WATSON
Mario Aistleithner
Katharina BAYER
Elsa MÜHLBACHER
Original Assignee
Hookipa Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Gmbh filed Critical Hookipa Biotech Gmbh
Publication of CY1124288T1 publication Critical patent/CY1124288T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Παρεχόμενοι στο παρόν είναι γενετικώς τροποποιημένοι αρενοϊικοί φορείς κατάλληλοι ως εμβόλια για αποτροπή και θεραπεία μολύνσεων και επανενεργοποίησης κυτταρομεγαλοϊού. Επίσης παρεχόμενες στο παρόν είναι φαρμακευτικές συνθέσεις και μέθοδοι για τη θεραπεία μολύνσεων και επανενεργοποίησης κυτταρομεγαλοϊού. Ειδικώς, παρεχόμενες στο παρόν είναι φαρμακευτικές συνθέσεις, εμβόλια και μέθοδοι θεραπείας μολύνσεων και επανενεργοποίησης κυτταρομεγαλοϊού.
CY20211100578T 2013-12-03 2021-06-29 Cmv εμβολια CY1124288T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911135P 2013-12-03 2013-12-03
US201462055699P 2014-09-26 2014-09-26
PCT/EP2014/076466 WO2015082570A1 (en) 2013-12-03 2014-12-03 Cmv vaccines

Publications (1)

Publication Number Publication Date
CY1124288T1 true CY1124288T1 (el) 2022-07-22

Family

ID=52232138

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100578T CY1124288T1 (el) 2013-12-03 2021-06-29 Cmv εμβολια

Country Status (18)

Country Link
US (3) US10111945B2 (el)
EP (2) EP3904522A1 (el)
JP (2) JP6818551B2 (el)
CN (2) CN105980570B (el)
AU (2) AU2014359276B2 (el)
CA (1) CA2932318C (el)
CY (1) CY1124288T1 (el)
DK (1) DK3077519T3 (el)
ES (1) ES2868427T3 (el)
HK (1) HK1226440A1 (el)
HR (1) HRP20211015T1 (el)
HU (1) HUE054579T2 (el)
LT (1) LT3077519T (el)
PL (1) PL3077519T3 (el)
PT (1) PT3077519T (el)
RS (1) RS61993B1 (el)
SI (1) SI3077519T1 (el)
WO (1) WO2015082570A1 (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2604695T3 (fi) 2007-12-27 2023-02-16 Replikaatiokyvyttömiä arenavirusvektoreita
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3904522A1 (en) 2013-12-03 2021-11-03 Hookipa Biotech GmbH Cmv vaccines
CN107223130A (zh) 2014-11-13 2017-09-29 日内瓦大学 作为疫苗载体的三片段沙粒病毒
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
AU2016342045A1 (en) 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
SI3371316T1 (sl) 2015-11-04 2023-02-28 Hookipa Biotech Gmbh Cepivo proti virusu hepatitisa B
HRP20221167T1 (hr) 2015-11-12 2022-12-09 Hookipa Biotech Gmbh Čestice arenavirusa kao cjepiva protiv raka
US11260090B2 (en) 2016-03-08 2022-03-01 University Of Vermont And State Agricultural College Modified arenavirus
MA44873A (fr) 2016-04-15 2019-03-13 Univ Pennsylvania Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
JP6980780B2 (ja) * 2016-10-21 2021-12-15 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
CA3039356A1 (en) 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
BR112019021569A2 (pt) 2017-04-14 2020-05-12 Regenxbio Inc. Precursor de iduronato-2-sulfatase humana recombinante glicosilada (ids), método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo ii (mps ii)
WO2018204080A1 (en) * 2017-05-02 2018-11-08 The Scripps Research Institute Compositions and methods related to arenavirus immunogens
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
CN113271968A (zh) * 2018-10-17 2021-08-17 葛兰素史密丝克莱恩生物有限公司 经修饰的巨细胞病毒蛋白和稳定化的复合物
US20220023416A1 (en) * 2018-12-10 2022-01-27 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
AU2020377504A1 (en) 2019-11-07 2022-06-02 Universität Basel Arenaviruses as vectors
AU2021287508B2 (en) * 2020-06-09 2023-11-09 Km Biologics Co., Ltd. Fusion protein of pentamer and gB of cytomegalovirus, and vaccine containing said fusion protein
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
RU2756557C1 (ru) * 2020-11-02 2021-10-01 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов
BR112023016075A2 (pt) 2021-02-10 2023-11-21 Regenxbio Inc Método para tratar hepatoesplenomegalia, método de distribuição de um raav que codifica hids, método para tratar um sujeito humano, método de tratamento de um sujeito humano, método para determinar a eficácia do tratamento, método para identificar um sujeito como tendo mps ii
EP4337320A1 (en) 2021-05-13 2024-03-20 Hookipa Biotech GmbH Arenaviruses as vectors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2607712B2 (ja) * 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2403681A1 (en) * 2000-03-21 2001-09-27 Genzyme Corporation Therapeutic anti-cytomegalovirus compounds
DE102004034461B4 (de) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
FI2604695T3 (fi) 2007-12-27 2023-02-16 Replikaatiokyvyttömiä arenavirusvektoreita
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
US20120093848A1 (en) * 2009-06-26 2012-04-19 Vectorite Biomedica Inc. Immunogenic composition comprising peptides derived from cytomegalovirus and the use thereof
MX2013004149A (es) * 2010-10-15 2013-09-02 Glaxosmithkline Biolog Sa Antigeno gb de citomegalovirus.
CN103597098A (zh) 2011-01-07 2014-02-19 斯洛伐克生物科学公司 病毒诊断
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
EP2729165B1 (en) * 2011-07-06 2017-11-08 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US8834307B2 (en) 2011-10-06 2014-09-16 Kawasaki Jukogyo Kabushiki Kaisha Belt type continuously variable transmission
EP2766385A2 (en) * 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
CA2878344A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
WO2014140301A1 (en) 2013-03-15 2014-09-18 Université De Genève Anti-mycobacterial vaccines
EP3904522A1 (en) 2013-12-03 2021-11-03 Hookipa Biotech GmbH Cmv vaccines
CN107223130A (zh) 2014-11-13 2017-09-29 日内瓦大学 作为疫苗载体的三片段沙粒病毒
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
SI3371316T1 (sl) 2015-11-04 2023-02-28 Hookipa Biotech Gmbh Cepivo proti virusu hepatitisa B
HRP20221167T1 (hr) 2015-11-12 2022-12-09 Hookipa Biotech Gmbh Čestice arenavirusa kao cjepiva protiv raka
AU2017266738B2 (en) 2016-05-18 2023-10-12 Hookipa Biotech Gmbh Tri-segmented Pichinde viruses as vaccine vectors
CA3039356A1 (en) 2016-11-04 2018-05-11 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
CN110719788A (zh) 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒
AU2020377504A1 (en) 2019-11-07 2022-06-02 Universität Basel Arenaviruses as vectors
IL298420A (en) 2020-05-29 2023-01-01 Hookipa Biotech Gmbh Cancer treatment strategies using RNA virus vectors

Also Published As

Publication number Publication date
EP3077519B1 (en) 2021-03-31
US11554169B2 (en) 2023-01-17
US20190247493A1 (en) 2019-08-15
WO2015082570A8 (en) 2015-11-26
CN115058452A (zh) 2022-09-16
CN105980570B (zh) 2022-06-07
CA2932318C (en) 2023-10-10
PL3077519T3 (pl) 2021-10-18
WO2015082570A1 (en) 2015-06-11
DK3077519T3 (en) 2021-06-14
PT3077519T (pt) 2021-05-13
SI3077519T1 (sl) 2021-07-30
EP3904522A1 (en) 2021-11-03
HUE054579T2 (hu) 2021-09-28
AU2021202541A1 (en) 2021-05-27
US20160296619A1 (en) 2016-10-13
CN105980570A (zh) 2016-09-28
EP3077519A1 (en) 2016-10-12
LT3077519T (lt) 2021-04-26
US20230181725A1 (en) 2023-06-15
US10111945B2 (en) 2018-10-30
ES2868427T3 (es) 2021-10-21
CA2932318A1 (en) 2015-06-11
JP7001807B2 (ja) 2022-02-04
HK1226440A1 (zh) 2017-09-29
RS61993B1 (sr) 2021-07-30
JP2017503482A (ja) 2017-02-02
AU2014359276B2 (en) 2021-01-28
HRP20211015T1 (hr) 2021-10-01
JP6818551B2 (ja) 2021-01-20
AU2014359276A1 (en) 2016-06-16
JP2021061848A (ja) 2021-04-22

Similar Documents

Publication Publication Date Title
CY1124288T1 (el) Cmv εμβολια
MX2018005569A (es) Vacunas contra el virus de la hepatitis b.
CY1123598T1 (el) Μακροκυκλικα πεπτιδια χρησιμα ως ανοσοδιαμορφωτες
CY1120893T1 (el) Μεθοδοι για αγωγη μολυνσεων ιου filoviridae
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
CY1123361T1 (el) Παραγωγο ισοϊνδολινης, ενδιαμεσο, μεθοδος παρασκευης, φαρμακευτικη συνθεση και χρηση αυτου
IL262963A (en) Three-segmented pichinde viruses as vaccine vectors
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
MA46024A (fr) Vaccin contre le virus de l'herpès simplex
ZA201708039B (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
MA43762A (fr) Vaccin contre le rsv
BR112018005779A2 (pt) repressores de htt e usos dos mesmos
MA52645A (fr) Vaccins contre le virus respiratoire
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
EA201790532A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса
DK3584252T3 (da) Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf
DK3142637T3 (da) Keratin treatment formulations and methods
EP3505620A4 (en) 2D ORGANOID FOR INFECTIONS AND GROWTH OF HUMAN DIARRHOEVIRUS AND USE OF THE TWO-DIMENSIONAL ORGANOID
EA201800148A1 (ru) Оспенная вакцина для лечения рака
CY1120607T1 (el) Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
PT3519569T (pt) Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses
EP3148566C0 (en) SYNTHETIC LONG PEPTIDES (SLP) FOR THERAPEUTIC VACCINATION AGAINST HEPATITIS B VIRUS INFECTION
CY1123574T1 (el) Αντιπολλαπλασιαστικες ενωσεις και φαρμακευτικες συνθεσεις και χρησεις αυτων
EP3194595A4 (en) Viral rna segments as immunomodulatory agents and vaccine components